dm+d
Unassigned
New Medicines
Severe eosinophilic asthma in adults and adolescents
Information
New molecular entity
GlaxoSmithKline
GlaxoSmithKline
Development and Regulatory status
Phase I Clinical Trials
Phase I Clinical Trials
Phase III Clinical Trials
Category
A long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody
The exact prevalence of eosinophilic asthma is unknown, however, it is estimated that approximately 10% of all asthma is categorized as severe. Eosinophilic asthma is most commonly diagnosed in adults 35-50 years old, although it is sometimes seen in even older adults and pediatric patients [1]. 5.4 million people in the UK are currently receiving treatment for asthma: 1.1 million children (1 in 11) and 4.3 million adults (1 in 12) [2].
Severe eosinophilic asthma in adults and adolescents
Subcutaneous injection